Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcus aureus endophthalmitis

Current Eye Research

Volumn 32, Issue 4, 2007, Pages 337-344

  Ermis, Sitki Samet ^a,c   Cetinkaya, Zafer ^a   Kiyici, Halil ^b   Inan, Umit Ubeyt ^a   Ozturk, Faruk ^a  

^a AFYON KOCATEPE UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

^c Dervispasa Mah Pirireis Sk   (Turkey)

Author keywords

Dexamethasone; Endophthalmitis; Moxifloxacin; Staphylococcus aureus

Indexed keywords

DEXAMETHASONE; MOXIFLOXACIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; CHOROID; CILIARY BODY; CLINICAL EXAMINATION; COLONY FORMING UNIT; CONTROLLED STUDY; CORNEA; DRUG EFFICACY; ENDOPHTHALMITIS; HISTOPATHOLOGY; IRIS; KRUSKAL WALLIS TEST; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PRIORITY JOURNAL; RANK SUM TEST; RETINA; SCORING SYSTEM; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS ENDOPHTHALMITIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VITREOUS BODY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; AZA COMPOUNDS; COLONY COUNT, MICROBIAL; DEXAMETHASONE; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; EDEMA; ENDOPHTHALMITIS; HYPEREMIA; INJECTIONS; QUINOLINES; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VITREOUS BODY;

EID: 34247368888     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680701215595     Document Type: Article

References (36)

1. Callegan MC, Engelbert M, Parke DW 2nd, et al. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev. 2002;15:111-124.
2. Barry P, Behrens-Baumann W, Pleyer U, Seal D. ESCRS Guidelines on Prevention, Investigation and Management of Post-operative Endophthalmitis, Version 1. Dublin: European Society of Cataract & Refractive Surgeons; 2005.
3. Engstrom RE Jr, Mondino BJ, Glasgow BJ, et al. Immune response to Staphylococcus aureus endophthalmitis in a rabbit model. Invest Ophthalmol Vis Sci. 1991;32:1523-1533.
4. Speaker MG, Milch FA, Shah MK, et al. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology. 1991;98:639-649.
5. Smith A, Pennefather PM, Kaye SB, Hart CA. Fluoroquinolones: place in ocular therapy. Drugs. 2001;61:747-761.
6. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.
7. Hariprasad SM, Mieler WE, Shah GK, et al. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. Trans Am Ophthalmol Soc. 2004;102:149-155.
8. Maxwell DP Jr, Brent BD, Diamond JG, Wu L. Effect of intravitreal dexamethasone on ocular histopathology in a rabbit model of endophthalmitis. Ophthalmology. 1991;98:1370-1375.
9. Ermis SS, Cetinkaya Z, Kiyici H, Ozturk F. Treatment of Staphylococcus epidermidis endophthalmitis with intravitreal moxifloxacin in a rabbit model. Tohoku J Exp Med. 2005;205:223-229.
10. Pleyer U, Mondino BJ, Adamu S.A., et al. Immune response to Staphylococcus epidermidis-induced endophthalmitis in a rabbit model. Invest Ophthalmol Vis Sci. 1992;33:2650-2663.
11. Meredith TA, Aguilar HE, Miller MJ, et al. Comparative treatment of experimental Staphylococcus epidermidis endophthalmitis. Arch Ophthalmol. 1990;108:857-860.
12. Aguilar HE, Meredith TA, Drews C, et al. Comparative treatment of experimental Staphylococcus aureus endophthalmitis. Am J Ophthalmol. 1996;121:310-317.
13. Kowalski RP, Romanowski EG, Mah FS, et al. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol. 2004;138:33-37.
14. Katz HR, Masket S, Lane SS, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea. 2005;24:955-958.
15. Costello P, Bakri SJ, Beer PM, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina. 2006;26:191-195.
16. Bronner S, Jehl F, Peter JD, et al. Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors. Antimicrob Agents Chemother. 2003;47:1621-1629.
17. Vedantham V, Lalitha P, Velpandian T, et al. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Eye 2005.
18. Kowalski RP, Romanowski EG, Mah FS, et al. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol. 2005;140:497-504.
19. Iyer MN, He F, Wensel TG, et al. Clearance of intravitreal moxifloxacin. Invest Ophthalmol Vis Sci. 2006;47:317-319.
20. Ficker L, Meredith TA, Gardner S, Wilson LA. Cefazolin levels after intravitreal injection. Effects of inflammation and surgery. Invest Ophthalmol Vis Sci. 1990;31:502-505.
21. Aydin E, Kazi AA, Peyman GA, Esfahani MR. Intravitreal toxicity of moxifloxacin. Retina. 2006;26:187-190.
22. Foster RE, Martinez JA, Murray TG, et al. Useful visual outcomes after treatment of Bacillus cereus endophthalmitis. Ophthalmology. 1996;103:390-397.
23. Baum J, Peyman GA, Barza M. Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus. Surv Ophthalmol. 1982;26:204-206.
24. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;13:1479-1496.
25. Ferencz JR, Assia EI, Diamantstein L, Rubinstein E. Vancomycin concentration in the vitreous after intravenous and intravitreal administration for postoperative endophthalmitis. Arch Ophthalmol. 1999;117:1023-1027.
26. Peyman GA, Vastine DW, Raichand M. Symposium: postoperative endophthalmitis: experimental aspects and their clinical application. Ophthalmology. 1978;85:374-385.
27. Meredith TA, Trabelsi A, Miller MJ, et al. Spontaneous sterilization in experimental Staphylococcus epidermidis endophthalmitis. Invest Ophthalmol Vis Sci. 1990;31:181-186.
28. Driebe WT Jr, Mandelbaum S, Forster RK, et al. Pseudophakic endophthalmitis. Diagnosis and management. Ophthalmology. 1986;93:442-448.
29. Yoshizumi MO, Lee GC, Equi RA, et al. Timing of dexamethasone treatment in experimental staphylococcus aureus endophthalmitis. Retina. 1998;18:130-135.
30. Jett BD, Jensen HG, Atkuri RV, Gilmore MS. Evaluation of therapeutic measures for treating endophthalmitis caused by isogenic toxin-producing and toxin-nonproducing Enterococcus faecalis strains. Invest Ophthalmol Vis Sci. 1995;36:9-15.
31. Meredith TA, Aguilar HE, Drews C, et al. Intraocular dexamethasone produces a harmful effect on treatment of experimental Staphylococcus aureus endophthalmitis. Trans Am Ophthalmol Soc. 1996;94:241-252.
32. Merino G, Fujino Y, Hanashiro RK. Lipoteichoic acid as an inducer of acute uveitis in the rat. Invest Ophthalmol Vis Sci. 1998;39:1251-1256.
33. Callegan MC, Booth MC, Jett BD, Gilmore MS. Pathogenesis of gram-positive bacterial endophthalmitis. Infect Immun. 1999;67:3348-3356.
34. Chen J, Fujino Y, Takahashi T. Experimental uveitis induced by intravitreal or intravenous lipoteichoic acid in rabbits. Jpn J Ophthalmol. 1999;43:368-374.
35. Vallar R,Wilson CA, Park SS. Effect of intravitreal dexamethasone on the blood-ocular barrier breakdown associated with pneumococcal endophthalmitis in rabbits. ARVO abstracts. Invest Ophthalmol Vis Sci. 1995;36(Suppl):S790.
36. Gan IM, Ugahary LC, van Dissel JT, et al. Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefes Arch Clin Exp Ophthalmol. 2005;243:1200-1205.